FIRST AIRED: December 13, 2017

Nice work! Enjoy the show!

×

You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!

×

Transcript

00:00:00
>> Four-time Tour de France winner Chris Froome failed a urine test during his Vuelta Espana win in September, but says he’s done nothing wrong and will provide quote, whatever information is required. The British cyclist had doubled the allowed level of a legal asthma drug in his system. It states that he followed the team doctors advice when he took an increased dosage.
00:00:22
Reuters Allen Baldwin, says the drug in question, Salbutamol has been around for years.>> Any regular asthma sufferer will take it with an inhaler, it is very common drug. But it has been used a lot in sports, legitimately and illegitimately. Athletes have used it for a long time, particularly in say, Nordic skiing and cycling for dealing with asthma when they're training.
00:00:47
But also it does have benefits that excessive use can be considered doping.>> Cycling's world governing body, UCI, now wants more details, but says Froome is not suspended. The sample showed his levels were at 2,000 nanograms per mililiter, that compares to the world anti-doping agency's threshold of 1,000.
00:01:09
Froome has suffered from asthma since childhood. In his statement he says he increased his dosage when his symptoms got worse, and welcomed the decision to examine the test results, which could potentially strip him of his title.>> There are a number of precedents ranging from an Italian rider in 2007 who was actually suspended, given a 12 month ban for excessive use of Salbutamol.
00:01:34
But there are other cases where it's been accepted that this is just an adverse finding. It doesn't actually constitute doping or there has to be any sanction necessarily.>> Froome became the first Britain to win the three week race around Spain, following his fourth Tour de France victory in July.